Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
muscarinic receptor agonist |
| gptkbp:administeredBy |
oral tablet
|
| gptkbp:CASNumber |
123355-63-9
|
| gptkbp:clinicalTrialPhase |
Phase 3 (as of 2023)
|
| gptkbp:combination_product_name |
gptkb:KarXT
|
| gptkbp:combines |
gptkb:trospium
|
| gptkbp:developedBy |
treatment of Alzheimer's disease
treatment of schizophrenia |
| gptkbp:discoveredBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:discoveredIn |
1990s
|
| gptkbp:hasMolecularFormula |
C21H23NO2
|
| gptkbp:hasSMILES |
CCCCCCOc1nnc(c1)C2=CNCC=C2
|
| https://www.w3.org/2000/01/rdf-schema#label |
xanomeline
|
| gptkbp:IUPACName |
gptkb:3-[3-(hexyloxy)-1,2,5-thiadiazol-4-yl]-1,2,5,6-tetrahydropyridine
|
| gptkbp:molecularWeight |
321.41 g/mol
|
| gptkbp:PubChem_CID |
CHEMBL19021
60946 |
| gptkbp:sideEffect |
nausea
vomiting diarrhea salivation excessive sweating |
| gptkbp:targets_receptor |
gptkb:muscarinic_acetylcholine_receptor_M1
gptkb:muscarinic_acetylcholine_receptor_M4 |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:bfsParent |
gptkb:KarXT
|
| gptkbp:bfsLayer |
6
|